Department of Communicable Diseases, National Centre of Epidemiology, Institute of Health Carlos III, Madrid, Spain.
Department of Communicable Diseases, National Centre of Epidemiology, Institute of Health Carlos III, Madrid, Spain.
J Infect. 2024 Nov;89(5):106292. doi: 10.1016/j.jinf.2024.106292. Epub 2024 Sep 26.
Our aim was to estimate the risk of pneumonia, admission to intensive care unit (ICU) or death in individuals ≥65 years old admitted to hospital with RSV, compared to influenza or COVID-19.
We included hospitalised patients from Severe Acute Respiratory Infection Surveillance in Spain between 2021-2024, aged ≥65 years, laboratory confirmed for RSV, influenza or SARS-CoV-2. Using a binomial regression with logarithmic link, we estimated the relative risk (RR) of pneumonia, ICU admission and in-hospital mortality, in patients with RSV compared to influenza or SARS-CoV-2, adjusting for age, sex, season and comorbidities. We stratified the estimates by vaccination status for influenza or SARS-CoV2.
Among patients unvaccinated for influenza or SARS-CoV-2, those with RSV had similar or lower risk of pneumonia [vs. influenza: RR= 0.91 (95% Confidence Interval: 0.72-1.16); vs. SARS-CoV-2: 0.81 (0.67-0.98)], ICU admission [vs. influenza: 0.93 (0.41-2.08); vs. SARS-CoV-2: 1.10 (0.61-1.99)] and mortality [vs. influenza: 0.64 (0.32-1.28); vs. SARS-CoV-2: 0.56 (0.30-1.04)]. Among the vaccinated, results were largely similar except for a higher risk of ICU admission with RSV [vs. influenza: 2.13(1.16-3.89); vs. SARS-CoV-2: 1.83 (1.02-3.28)] CONCLUSIONS: RSV presented similar or lower intrinsic severity than influenza or SARS-CoV2. Among vaccinated patients, RSV was associated to higher ICU-admission, suggesting the potential for preventive RSV vaccination.
我们的目的是评估≥65 岁因 RSV 住院的个体患肺炎、入住重症监护病房(ICU)或死亡的风险,与流感或 COVID-19 相比。
我们纳入了 2021-2024 年西班牙严重急性呼吸道感染监测中≥65 岁、实验室确诊为 RSV、流感或 SARS-CoV-2 的住院患者。使用二项回归和对数链接,我们估计了与流感或 SARS-CoV-2 相比,RSV 患者患肺炎、入住 ICU 和院内死亡的相对风险(RR),并根据年龄、性别、季节和合并症进行了调整。我们根据流感或 SARS-CoV-2 的疫苗接种状态对估计值进行了分层。
在未接种流感或 SARS-CoV-2 疫苗的患者中,RSV 患者患肺炎的风险相似或更低[与流感相比:RR=0.91(95%置信区间:0.72-1.16);与 SARS-CoV-2 相比:0.81(0.67-0.98)]、入住 ICU 的风险[与流感相比:0.93(0.41-2.08);与 SARS-CoV-2 相比:1.10(0.61-1.99)]和死亡率[与流感相比:0.64(0.32-1.28);与 SARS-CoV-2 相比:0.56(0.30-1.04)]。在接种疫苗的患者中,结果基本相似,除了 RSV 导致 ICU 入院风险增加外[与流感相比:2.13(1.16-3.89);与 SARS-CoV-2 相比:1.83(1.02-3.28)]。
RSV 的内在严重程度与流感或 SARS-CoV2 相似或更低。在接种疫苗的患者中,RSV 与更高的 ICU 入院率相关,这表明 RSV 疫苗接种具有潜在的预防作用。